Life Sciences

Use our digital biomarkers to increase trial success
and drive drug commercialization

  • Enhance clinical trials:
    Automate and optimize key trial assessments and pre-trial stratification with off-the-shelf digital biomarkers
  • Co-develop and co-promote:
    Identify new digital biomarker opportunities and pursue partnered co-development and co-promotion

Healthcare Providers

Translate Clinical Decision-Making Into Data Science

  • Enhance clinical practice with machine learning-driven biomarkers in critical and rare diseases
  • Add computer science-driven automation to challenging and time-consuming clinical assessments
  • Research Use Only

About Us

imvaria was founded in 2019 by a team of physician-engineers from Stanford and Google, seeking to empower clinicians and improve patient outcomes through the development and application of modern computer science techniques to complex and serious clinical problems. The company's Digital Biomarker Platform enables non-invasive diagnostic and therapeutic patient stratification via data science and machine learning.

Management Team
Co-Founder Dr. Joshua Reicher
Prior experience includes work in Google's AI group, multiple publications in machine learning in medicine, and extensive experience writing code. Dr. Reicher is on clinical faculty as a radiologist and computer science researcher at Stanford / Palo Alto VA.
Co-Founder Dr. Michael Muelly
Prior experience includes work as a Product Manager at Google Cloud's Healthcare group, co-founding of both imaging and network security start-ups, and extensive experience writing code. Dr. Muelly is on clinical faculty as a radiologist and computer science researcher at Stanford.
Medical Advisor Dr. Joshua Mooney
Leading pulmonary and rare disease expert at Stanford. Board-certified in pulmonary and critical care medicine. Key opinion leader and clinical trials principal investigator.